CerebroPlex (N-acetyl-L-tyrosine)

N-acetyl-L-tyrosine (NALT) is an acetylated form of the amino acid L-tyrosine, a precursor to the catecholamine neurotransmitters dopamine, norepinephrine, and epinephrine. Its acetylated structure increases water solubility compared to L-tyrosine, though evidence that this meaningfully improves bioavailability or cognitive outcomes in humans remains limited.

Origin & History

CerebroPlex (N-acetyl-L-tyrosine, or NALT) is a branded form of N-acetyl-L-tyrosine, a synthetically modified derivative of the amino acid L-tyrosine designed to improve water solubility. It is produced through chemical acylation of L-tyrosine (derived from E. coli fermentation) with acetic anhydride or acetyl chloride, followed by purification steps to achieve high purity.

Historical & Cultural Context

N-acetyl-L-tyrosine has no traditional or historical medicinal use, as it is a modern synthetic compound developed for improved solubility. It does not appear in any traditional medicine systems and was created specifically for pharmaceutical and nutritional applications.

Health Benefits

• Enhanced tyrosine availability for neurotransmitter synthesis - theoretical benefit based on mechanism, no clinical evidence provided • Improved water solubility compared to L-tyrosine - established chemical property, clinical significance unclear • Potential stress support through catecholamine precursor activity - mechanistic rationale only, no human trials cited • Possible cognitive support via dopamine/norepinephrine pathways - theoretical based on biochemistry, no clinical validation • Parenteral nutrition applications - limited evidence from one 1985 study (PMID: 3925425)

How It Works

N-acetyl-L-tyrosine is deacetylated in vivo by hepatic and renal acylases to release free L-tyrosine, which is then hydroxylated by tyrosine hydroxylase (TH) — the rate-limiting enzyme — converting it to L-DOPA, a direct precursor to dopamine. Dopamine is subsequently converted to norepinephrine via dopamine beta-hydroxylase (DBH), and further to epinephrine via phenylethanolamine N-methyltransferase (PNMT). By replenishing the L-tyrosine pool, NALT theoretically sustains catecholamine synthesis under conditions of high neurological demand or stress-induced depletion.

Scientific Research

Clinical evidence for N-acetyl-L-tyrosine is extremely limited. Only one human study from 1985 (PMID: 3925425) examined NALT as an intravenous tyrosine source during parenteral nutrition using radiolabeled compounds, but cognitive or neurological outcomes were not reported. No randomized controlled trials, meta-analyses, or large-scale human studies evaluating oral supplementation or cognitive benefits were identified.

Clinical Summary

Direct clinical trials on the branded CerebroPlex formulation are not publicly available. Research on parent compound L-tyrosine in humans — including studies of 100–150 mg/kg doses in military and cognitive stress settings — shows modest improvements in working memory and mood under acute stress, but effects in healthy, non-stressed individuals are minimal. A 2015 meta-analysis of L-tyrosine studies found consistent but small cognitive benefits primarily under conditions of catecholamine depletion. NALT-specific human trials are sparse, and whether NALT's acetylated form offers superior clinical outcomes over equivalent doses of L-tyrosine has not been established in controlled studies.

Nutritional Profile

N-acetyl-L-tyrosine (NALT) is a acetylated derivative of the amino acid L-tyrosine, not a whole food ingredient. Macronutrient contribution is negligible at typical supplemental doses (300–750 mg/day). Protein content: NALT is an amino acid derivative contributing approximately 0.3–0.75 g of amino acid equivalent per typical dose, though bioconversion to free L-tyrosine is required for metabolic utility. No fiber, significant fat, or carbohydrate content. No vitamins or minerals present. Bioactive compound: NALT itself at ~99% purity in pharmaceutical-grade forms; molecular weight 238.24 g/mol compared to L-tyrosine at 181.19 g/mol, meaning per gram of NALT, approximately 76% by mass is the active tyrosine moiety. Bioavailability note: NALT is water-soluble (significantly more so than L-tyrosine), which was the rationale for its development; however, human pharmacokinetic studies (Magnusson et al., 1994; van Spronsen et al.) indicate NALT has poor renal reabsorption and is largely excreted intact in urine rather than deacetylated to free tyrosine, suggesting bioconversion efficiency may be substantially lower than plain L-tyrosine. Free L-tyrosine serves as precursor to catecholamines (dopamine, norepinephrine, epinephrine) and thyroid hormones; plasma tyrosine elevation from NALT supplementation is documented but potentially less efficient gram-for-gram than L-tyrosine itself.

Preparation & Dosage

No clinically studied dosage ranges for oral supplementation (powder, capsule, or extract forms) are available in the research. The only documented use was intravenous administration in parenteral nutrition contexts, but specific doses were not provided. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

L-tyrosine, B-complex vitamins, vitamin C, iron, folate

Safety & Interactions

N-acetyl-L-tyrosine is generally considered safe at typical supplemental doses of 300–2000 mg/day, with side effects including nausea, heartburn, headache, and fatigue reported at higher doses. Because NALT raises catecholamine levels, it may interact with MAO inhibitors (MAOIs), potentially causing hypertensive crisis, and should be used cautiously alongside stimulant medications such as amphetamines or thyroid hormones like levothyroxine. Individuals with hyperthyroidism, Graves' disease, or melanoma should avoid tyrosine supplementation, as tyrosine is a precursor to both thyroid hormones and melanin. Pregnant and breastfeeding women should consult a physician before use, as safety data in these populations is insufficient.